Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry

BACKGROUND: Large-scale real-world data of the 8-week glecaprevir/pibrentasvir (GLE/PIB) therapy for treatment-naïve patients of chronic hepatitis C virus (HCV) infection with compensated cirrhosis is scarce. METHODS: The TASL HCV Registry (TACR) is an ongoing nationwide registry program that aims t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Te-Sheng, Huang, Chung-Feng, Kuo, Hsing-Tao, Lo, Ching-Chu, Huang, Chien-Wei, Chong, Lee-Won, Cheng, Pin-Nan, Yeh, Ming-Lun, Peng, Cheng-Yuan, Cheng, Chien-Yu, Huang, Jee-Fu, Bair, Ming-Jong, Lin, Chih-Lang, Yang, Chi-Chieh, Wang, Szu-Jen, Hsieh, Tsai-Yuan, Lee, Tzong-Hsi, Lee, Pei-Lun, Wu, Wen-Chih, Lin, Chih-Lin, Su, Wei-Wen, Yang, Sheng-Shun, Wang, Chia-Chi, Hu, Jui-Ting, Mo, Lein-Ray, Chen, Chun-Ting, Huang, Yi-Hsiang, Chang, Chun-Chao, Huang, Chia-Sheng, Chen, Guei-Ying, Kao, Chien-Neng, Tai, Chi-Ming, Liu, Chun-Jen, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Kao, Jia-Horng, Lin, Han-Chieh, Chuang, Wang-Long, Chen, Chi-Yi, Tseng, Kuo-Chih, Hung, Chao-Hung, Yu, Ming-Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042416/
https://www.ncbi.nlm.nih.gov/pubmed/36973633
http://dx.doi.org/10.1007/s12072-023-10506-z

Ejemplares similares

Ejemplares similares